A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

Clinical trial NCT07609706 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07609706
Sponsor: GlaxoSmithKline
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2026-10-23
Primary completion: 2031-08-22
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.